Table 4.
Progression-free survival (PFS), overall survival (OS), and duration of response (DOR) for the entire cohort and by starting lenvatinib dose.
| Characteristic | N | Progression # | Median PFS, months (95% CI) | 1-year PFS rate (95% CI) | HR (95% CI) | P value |
|---|---|---|---|---|---|---|
|
| ||||||
| Entire cohort | 43 | 36 | 6 (4.2–8.9) | 21% (10.1%-34.5%) | ||
| Reduced dose | 20 | 15 | 9.1 (4.1–12.6) | 35% (15.7%-55.2%) | 1 | .02 |
| Standard dose | 23 | 21 | 5.2 (3.1–6.7) | 6.3% (0.5%-24%) | 2.23 (1.11–4.47) | |
| Characteristic | N | Death # | Median OS, months (95% CI) | 1-year OS rate (95% CI) | HR (95% CI) | P value |
|
| ||||||
| Entire cohort | 43 | 23 | 18.3 (9.3-NE) | 61.7% (45.3%-74.6%) | ||
| Reduced dose | 20 | 9 | Not Reached | 69.1% (43.6%-84.8%) | 1 | .27 |
| Standard dose | 23 | 14 | 14.1 (5.7–27.3) | 55.4% (33%-73.1%) | 1.6 (0.69-3.71) | |
| Characteristic | PR | Progression/Death # | Median DOR, months (95% CI) | 1-year DOR rate (95% CI) | HR (95% CI) | P value |
|
| ||||||
| Entire cohort | 13 | 9 | 5.7 (2.2-NE) | 28.8% (7.9%-54.5%) | ||
| Reduced dose | 6 | 3 | 8.3 (1.9-NE) | 50% (11.1%-80.4%) | .09 | |
| Standard dose | 7 | 6 | 3.5 (1.3–6.1) | Not Reached | 3.64 (0.72-18.29) | |
P values obtained using log-rank test.
Reduced dose: 10 mg or 14 mg starting lenvatinib dosage; standard dose: 20 mg starting lenvatinib dose. PFS=progression-free survival; OS=overall survival; DOR=duration of response; CI=confidence interval; HR=hazard ratio; PR=partial response.